MYOS RENS Technology Company Profile (NASDAQ:MYOS)

About MYOS RENS Technology (NASDAQ:MYOS)

MYOS RENS Technology logoMYOS RENS Technology Inc. (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity. The Company is focused on the discovery, development, and commercialization of nutritional supplements, functional foods, therapeutic products, and other technologies for maintaining the health and performance of muscle tissue. MYOS is evaluating the modulation of myostatin. Its research is focused on developing strategies and therapeutic interventions to address muscle related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases. The Company, through its subsidiary, holds the intellectual property pertaining to Fortetropin, which is a dietary supplement.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MYOS
  • CUSIP: N/A
  • Web: www.myoscorp.com
Capitalization:
  • Market Cap: $12.21 million
  • Outstanding Shares: 5,844,000
Average Prices:
  • 50 Day Moving Avg: $2.35
  • 200 Day Moving Avg: $2.44
  • 52 Week Range: $1.02 - $6.98
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $282,000.00
  • Price / Sales: 43.31
  • Book Value: $1.05 per share
  • Price / Book: 1.99
Profitability:
  • EBIDTA: ($3,960,000.00)
  • Net Margins: -1,466.77%
  • Return on Equity: -87.17%
  • Return on Assets: -68.69%
Debt:
  • Current Ratio: 4.07%
  • Quick Ratio: 2.50%
Misc:
  • Average Volume: 385,200 shs.
  • Beta: 1.46
  • Short Ratio: 2.44
 

Frequently Asked Questions for MYOS RENS Technology (NASDAQ:MYOS)

What is MYOS RENS Technology's stock symbol?

MYOS RENS Technology trades on the NASDAQ under the ticker symbol "MYOS."

How were MYOS RENS Technology's earnings last quarter?

MYOS RENS Technology Inc (NASDAQ:MYOS) issued its earnings results on Monday, November, 14th. The company reported ($0.17) EPS for the quarter. The business had revenue of $0.04 million for the quarter. MYOS RENS Technology had a negative net margin of 1,466.77% and a negative return on equity of 87.17%. View MYOS RENS Technology's Earnings History.

Who are some of MYOS RENS Technology's key competitors?

How do I buy MYOS RENS Technology stock?

Shares of MYOS RENS Technology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of MYOS RENS Technology stock cost?

One share of MYOS RENS Technology stock can currently be purchased for approximately $2.09.

Analyst Ratings

Consensus Ratings for MYOS RENS Technology (NASDAQ:MYOS) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for MYOS RENS Technology (NASDAQ:MYOS)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for MYOS RENS Technology (NASDAQ:MYOS)
Earnings by Quarter for MYOS RENS Technology (NASDAQ:MYOS)
Earnings History by Quarter for MYOS RENS Technology (NASDAQ:MYOS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2016Q3 2016($0.17)$0.04 millionViewN/AView Earnings Details
11/14/2014Q3 2014($0.24)($0.73)$1.90 million$0.11 millionViewN/AView Earnings Details
8/14/2014Q214($0.20)($0.32)$1.70 million$1.68 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for MYOS RENS Technology (NASDAQ:MYOS)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for MYOS RENS Technology (NASDAQ:MYOS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for MYOS RENS Technology (NASDAQ:MYOS)
Insider Ownership Percentage: 58.30%
Institutional Ownership Percentage: 2.63%
Insider Trades by Quarter for MYOS RENS Technology (NASDAQ:MYOS)
Insider Trades by Quarter for MYOS RENS Technology (NASDAQ:MYOS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/23/2016Zhengguang LyuDirectorBuy50,000$1.70$85,000.00View SEC Filing  
9/6/2016Zhengguang LyuDirectorBuy23,505$1.60$37,608.00View SEC Filing  
6/17/2016Zhengguang LyuDirectorBuy10,000$1.65$16,500.00View SEC Filing  
4/8/2016Joseph MannelloDirectorBuy4,417$1.96$8,657.32View SEC Filing  
4/5/2016Joseph MannelloDirectorBuy6,128$1.75$10,724.00View SEC Filing  
9/29/2015Robert J. HaririDirectorBuy2,300$2.68$6,164.00View SEC Filing  
9/25/2015Robert J. HaririDirectorBuy12,150$2.44$29,646.00View SEC Filing  
9/11/2015Robert J. HaririDirectorBuy4,000$1.73$6,920.00View SEC Filing  
9/8/2015Robert J. HaririDirectorBuy25,250$1.71$43,177.50View SEC Filing  
9/4/2015Louis J AronneDirectorBuy5,000$1.76$8,800.00View SEC Filing  
8/28/2015Robert J HaririDirectorBuy2,750$1.74$4,785.00View SEC Filing  
12/4/2014Robert J HaririDirectorBuy2,200$8.16$17,952.00View SEC Filing  
8/18/2014Peter DiamandisDirectorBuy3,444$14.51$49,972.44View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for MYOS RENS Technology (NASDAQ:MYOS)
Latest Headlines for MYOS RENS Technology (NASDAQ:MYOS)
Source:
DateHeadline
prnewswire.com logoHow These Generic Drugs Stocks are Faring? -- MYOS RENS Technology, Akari Therapeutics, Flexion Therapeutics, and Zynerba Pharma
www.prnewswire.com - May 19 at 7:13 PM
finance.yahoo.com logoMYOS RENS Will Be Silver Sponsor at International Conference on Frailty and Sarcopenia Research (ICFSR)
finance.yahoo.com - April 24 at 3:35 PM
finance.yahoo.com logoMYOS RENS enters into agreement with Kansas State University to study impact of Fortetropin® on reducing muscle loss in dogs after joint surgery
finance.yahoo.com - April 18 at 10:14 AM
finance.yahoo.com logoMYOS RENS Technology, Inc. :MYOS-US: Earnings Analysis: Q4, 2016 By the Numbers : April 6, 2017
finance.yahoo.com - April 7 at 11:24 AM
us.rd.yahoo.com logoMYOS RENS Technology to host April 4 interactive conference call on "Qurr" product launch
us.rd.yahoo.com - March 31 at 9:26 AM
finance.yahoo.com logoAre you Qurr-ious? MYOS Rens Technology Inc. Launches Qurr Product Line Powered by Fortetropin®, an All-Natural Ingredient Clinically Proven to Increase Muscle Size and Mass
finance.yahoo.com - March 13 at 10:13 AM
finance.yahoo.com logo'Qurr' line of revolutionary muscle-health and muscle-building products in newly-enhanced form set for March rollout
finance.yahoo.com - March 1 at 6:51 PM
biz.yahoo.com logoMYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex
biz.yahoo.com - February 21 at 6:13 PM
biz.yahoo.com logoMYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Ri
us.rd.yahoo.com - February 15 at 2:17 AM
biz.yahoo.com logoMYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, F
biz.yahoo.com - February 8 at 7:36 PM
finance.yahoo.com logoKey Catalyst That Could Send Biotechs Soaring in 2017: Today's Reports on MYOS RENS Technology and Actinium Pharmaceuticals
finance.yahoo.com - February 6 at 9:40 AM
us.rd.yahoo.com logo2:55 pm MYOS RENS Tech. commences $2.125 common stock offering; to sell 500k shares at $4.25/share
us.rd.yahoo.com - February 4 at 5:31 AM
finanznachrichten.de logoMYOS RENS TECHNOLOGY INC
www.finanznachrichten.de - February 4 at 12:30 AM
streetinsider.com logoMYOS RENS Tech (MYOS) Reports $2.13M Registered Direct Offering of Common Stock
www.streetinsider.com - February 3 at 7:28 PM
marketwatch.com logoMYOS RENS Technology Inc. Announces $2,125,000 Registered Direct Offering
www.marketwatch.com - February 3 at 7:28 PM
finance.yahoo.com logoDr. Robert Hariri, stem cell pioneer and chairman of MYOS RENS Technology, states that 'healthy muscle is key to overall health and wellness'
finance.yahoo.com - January 30 at 9:31 AM
biz.yahoo.com logoMYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other
biz.yahoo.com - January 11 at 7:21 PM
biz.yahoo.com logoMYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - December 22 at 7:02 PM
biz.yahoo.com logoMYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - November 25 at 11:34 AM
finance.yahoo.com logo8:03 am MYOS RENS Tech. Announces Publication of Fortetropin Human Clinical Trial Manuscript demonstrating that it increased lean body mass, increased muscle thickness, and decreased markers of protein breakdown
finance.yahoo.com - September 29 at 11:25 AM
reuters.com logoBRIEF-Myos Rens Technology appoints Joseph Mannello interim CEO
www.reuters.com - August 31 at 11:21 AM
biz.yahoo.com logoMYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events
biz.yahoo.com - August 24 at 6:07 PM
biz.yahoo.com logoMYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - June 29 at 4:17 PM
biz.yahoo.com logoMYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant
biz.yahoo.com - May 20 at 5:26 PM
biz.yahoo.com logoMYOS RENS TECHNOLOGY INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - May 13 at 8:34 AM
finance.yahoo.com logoMYOS Reports Positive Results From Fortetropin(R) Clinical Study
finance.yahoo.com - April 22 at 3:00 PM
biz.yahoo.com logoMYOS RENS TECHNOLOGY INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 30 at 5:53 PM
biz.yahoo.com logoMYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financ
biz.yahoo.com - March 22 at 4:33 PM
biz.yahoo.com logoMYOS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Cha
biz.yahoo.com - March 8 at 5:31 PM
finance.yahoo.com logoMYOS Corporation Announces Election of New Directors and Appointment of Ren Ren as Global Chairman
finance.yahoo.com - March 8 at 4:17 PM
biz.yahoo.com logoMYOS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events
biz.yahoo.com - February 4 at 5:21 PM

Social

Chart

MYOS RENS Technology (MYOS) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff